As a result, these studies did not lead to GLP-1 receptor agonists being highly adopted for use by people with T1D
protecting the drugs sequestered
In terms of the ROI, at the most tactical level: As we mapped above, key stakeholders do want GLP1s to be widespread (even insurance company want them they just want the coverage to be spaced out so they can factor the cost into premiums)
A shipment will arrive in 5-7 days with syringes, needles, and a vial of medication
The patient profile for GLP-1 drugs BMI over 30 with metabolic complications: Type 2 diabetes, prediabetes, or significant cardiovascular risk factors
So, while the stack doesn't directly push the testosterone button, it creates an environment where the button can be pushed more effectively and efficiently by the body's own natural mechanisms